Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/1/46 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588940324896768 |
|---|---|
| author | Jelena Petković-Dabić Ivana Binić Bojana Carić Ljiljana Božić Sanja Umičević-Šipka Nataša Bednarčuk Saša Dabić Mirna Šitum Snježana Popović-Pejičić Miloš P. Stojiljković Ranko Škrbić |
| author_facet | Jelena Petković-Dabić Ivana Binić Bojana Carić Ljiljana Božić Sanja Umičević-Šipka Nataša Bednarčuk Saša Dabić Mirna Šitum Snježana Popović-Pejičić Miloš P. Stojiljković Ranko Škrbić |
| author_sort | Jelena Petković-Dabić |
| collection | DOAJ |
| description | Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity. The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy. This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (<i>n</i> = 15), while the second was control (<i>n</i> = 16). The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; <i>p</i> = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; <i>p</i> = 0.002)). The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (<i>p</i> < 0.05). A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified, as well as a significant decrease in the level of low-density cholesterol (LDL) (<i>p</i> < 0.05). In conclusion, semaglutide, based on its systemic anti-inflammatory characteristics, could contribute to the treatment of psoriatic obese patients with T2DM. |
| format | Article |
| id | doaj-art-e3f68037e32647b0b2b5e24196a8db18 |
| institution | Kabale University |
| issn | 2218-273X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-e3f68037e32647b0b2b5e24196a8db182025-01-24T13:24:58ZengMDPI AGBiomolecules2218-273X2025-01-011514610.3390/biom15010046Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical TrialJelena Petković-Dabić0Ivana Binić1Bojana Carić2Ljiljana Božić3Sanja Umičević-Šipka4Nataša Bednarčuk5Saša Dabić6Mirna Šitum7Snježana Popović-Pejičić8Miloš P. Stojiljković9Ranko Škrbić10Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaFaculty of Medicine, University of Niš, 18000 Niš, SerbiaCenter for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaDepartment of Microbiology and Immunology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaCenter for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaCenter for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaFaculty of Medicine Foča, University of East Sarajevo, 71123 Istočno Sarajevo, Bosnia and HerzegovinaDepartment of Dermatology and Venerology, University Hospital Center “Sestre Milosrdnice”, University of Zagreb, 10000 Zagreb, CroatiaCenter for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaCenter for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaCenter for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and HerzegovinaPsoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity. The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy. This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (<i>n</i> = 15), while the second was control (<i>n</i> = 16). The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; <i>p</i> = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; <i>p</i> = 0.002)). The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (<i>p</i> < 0.05). A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified, as well as a significant decrease in the level of low-density cholesterol (LDL) (<i>p</i> < 0.05). In conclusion, semaglutide, based on its systemic anti-inflammatory characteristics, could contribute to the treatment of psoriatic obese patients with T2DM.https://www.mdpi.com/2218-273X/15/1/46psoriasisT2DMsemaglutidePASIDLQIcytokine |
| spellingShingle | Jelena Petković-Dabić Ivana Binić Bojana Carić Ljiljana Božić Sanja Umičević-Šipka Nataša Bednarčuk Saša Dabić Mirna Šitum Snježana Popović-Pejičić Miloš P. Stojiljković Ranko Škrbić Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial Biomolecules psoriasis T2DM semaglutide PASI DLQI cytokine |
| title | Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial |
| title_full | Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial |
| title_fullStr | Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial |
| title_full_unstemmed | Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial |
| title_short | Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial |
| title_sort | effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus an open label randomized clinical trial |
| topic | psoriasis T2DM semaglutide PASI DLQI cytokine |
| url | https://www.mdpi.com/2218-273X/15/1/46 |
| work_keys_str_mv | AT jelenapetkovicdabic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT ivanabinic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT bojanacaric effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT ljiljanabozic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT sanjaumicevicsipka effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT natasabednarcuk effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT sasadabic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT mirnasitum effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT snjezanapopovicpejicic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT milospstojiljkovic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial AT rankoskrbic effectsofsemaglutidetreatmentonpsoriaticlesionsinobesepatientswithtype2diabetesmellitusanopenlabelrandomizedclinicaltrial |